Literature DB >> 33359314

Regulation of the NLRP3 inflammasome with natural products against chemical-induced liver injury.

Jian Zou1, Sheng-Peng Wang1, Yi-Tao Wang1, Jian-Bo Wan2.   

Abstract

The past decades have witnessed significant progress in understanding the process of sterile inflammation, which is dependent on a cytosolic complex termed the nucleotide-binding oligomerization domain (NOD)-like receptor containing pyrin domain 3 (NLRP3) inflammasome. Activation of NLRP3 inflammasome requires two steps, including the activation of Toll-like receptor (TLR) by its ligands, resulting in transcriptional procytokine and inflammasome component activation, and the assembly and activation of NLRP3 inflammasome triggered by various danger signals, leading to caspase-1 activation, which could subsequently cleave procytokines into their active forms. Metabolic disorders, ischemia and reperfusion, viral infection and chemical insults are common pathogenic factors of liver-related diseases that usually cause tissue damage and cell death, providing numerous danger signals for the activation of NLRP3 inflammasome. Currently, natural products have attracted much attention as potential agents for the prevention and treatment of liver diseases due to their multitargets and nontoxic natures. A great number of natural products have been shown to exhibit beneficial effects on liver injury induced by various chemicals through regulating NLRP3 inflammasome pathways. In this review, the roles of the NLRP3 inflammasome in chemical-induced liver injury (CILI) and natural products that exhibit beneficial effects in CILI through the regulation of inflammasomes were systematically summarized.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute liver failure; Chemical-induced liver injury; Inflammation; NLRP3 inflammasome; Natural products

Mesh:

Substances:

Year:  2020        PMID: 33359314     DOI: 10.1016/j.phrs.2020.105388

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  9 in total

Review 1.  Pro-Inflammatory Signalling PRRopels Cisplatin-Induced Toxicity.

Authors:  Ivan K Domingo; Asna Latif; Amit P Bhavsar
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

2.  An Experimental Study Reveals the Protective Effect of Autophagy against Realgar-Induced Liver Injury via Suppressing ROS-Mediated NLRP3 Inflammasome Pathway.

Authors:  Jing Yang; Jian Li; Haoqi Guo; Yuwei Zhang; Ziwei Guo; Yu Liu; Taoguang Huo
Journal:  Int J Mol Sci       Date:  2022-05-19       Impact factor: 6.208

3.  Novel Diacylglycerol Acetyltransferase 2 Inhibitors for Treating Liver Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-06-22       Impact factor: 4.632

Review 4.  NLRP3 Inflammasome: A Promising Therapeutic Target for Drug-Induced Toxicity.

Authors:  Shanshan Wei; Wanjun Ma; Bikui Zhang; Wenqun Li
Journal:  Front Cell Dev Biol       Date:  2021-04-12

5.  Red yeast rice ameliorates non-alcoholic fatty liver disease through inhibiting lipid synthesis and NF-κB/NLRP3 inflammasome-mediated hepatic inflammation in mice.

Authors:  Jian Zou; Chunyan Yan; Jian-Bo Wan
Journal:  Chin Med       Date:  2022-01-25       Impact factor: 5.455

6.  NLRP-3 Inflammasome: A Key Target, but Mostly Overlooked following SARS-CoV-2 Infection.

Authors:  Consolato M Sergi
Journal:  Vaccines (Basel)       Date:  2022-08-12

Review 7.  A Selective Review and Virtual Screening Analysis of Natural Product Inhibitors of the NLRP3 Inflammasome.

Authors:  Sherihan El-Sayed; Sally Freeman; Richard A Bryce
Journal:  Molecules       Date:  2022-09-21       Impact factor: 4.927

Review 8.  Inflammasomes and Fibrosis.

Authors:  Wen-Juan Zhang; Shu-Juan Chen; Shun-Chang Zhou; Su-Zhen Wu; Hui Wang
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

Review 9.  Thioredoxin interacting protein, a key molecular switch between oxidative stress and sterile inflammation in cellular response.

Authors:  Islam N Mohamed; Luling Li; Saifudeen Ismael; Tauheed Ishrat; Azza B El-Remessy
Journal:  World J Diabetes       Date:  2021-12-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.